The strongest result: a kidney drug that kept working for two years
The most significant verified development in this period is clinical, not financial. On 22 October 2026, Vor Bio announced final two-year results from its Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, a kidney disease.1 The headline measure is eGFR, a standard gauge of how well the kidneys filter blood. It normally declines in this disease. The company reports an annualized eGFR slope of -0.6 for treated patients against -5.7 mL/min/1.73 m² per year for placebo. That is a 5.1 difference (p<0.001).1 It also reports 89% and 81% lower risk of confirmed eGFR declines of at least 30% and at least 40%, respectively.1 Reductions in protein in the urine were sustained through 104 weeks after a move to every-other-week dosing, with what the company calls a favorable safety profile.1
A caution belongs next to those numbers. They come from the company's own press release, distributed on a newswire. Via News has measured that wire's record: 54% of 6,613 claims checked against their sources held up.1 The figures are plausible and statistically strong as reported, but we have not seen independent confirmation or the full trial data.
The result came out the week before the market turned. On 30 October, a $1 trillion tech selloff deepened fears of an AI bubble, as large AI bills and weak earnings spooked investors. The Nasdaq 100 had its worst day since June.2 If you hold a fund that tracks that index, that was its worst day in about four months.2
What a mature biotech's balance sheet looks like
Incyte, a cancer and inflammation drugmaker, gives the clearest verified financial picture. Its cash was $3.46 billion at the end of Q1 2026, $3.98 billion at Q2 and $3.28 billion at Q3.3 To picture that scale: it is close to the $3.6 billion Binance users pulled out in a single day (see below). Cash at year-end 2025 was $3.10 billion.3 The company's cash has moved a lot. It was $987 million at Q2 2024 and $1.69 billion at year-end 2024.3 The data shows the swings but not their causes, so we do not interpret them.
Cost of revenue, meaning what it costs the company to produce what it sells, has risen. It was $372 million for full-year 2025, against $312 million in 2024.4 In the most recent quarter, Q3 2026, it was $108.7 million against $99.0 million a year earlier.4 The earlier 2026 quarters rose faster: $104.5 million in Q1 against $73.2 million, and $105.0 million in Q2 against $78.8 million.4 The dossier carries no revenue figures for these periods, so we cannot say whether sales grew faster than costs.
One data point deserves a flag. Incyte's capital spending is recorded at exactly $48.7 million for both FY 2024 and FY 2025.5 Both entries are marked as canonical and sourced from SEC filings. Identical figures in consecutive years are possible but unusual, so we are noting them without drawing a conclusion.
The topic brief for this period also points to Incyte pancreatic-cancer data at the ESMO medical conference and strong demand for Eli Lilly's GLP-1 drugs. The verified record available to us contains no figures for either, so we do not state any.
Royalties show a product at work
BioArctic, the Swedish company behind the Alzheimer's drug Leqembi, is paid royalties by its partner Eisai. Eisai reported Leqembi sales of JPY 29.3 billion for Q2 2026, which produced a royalty of SEK 179 million to BioArctic, about 10% more than a year earlier.6 BioArctic says that year-earlier figure included a one-time stockpiling effect in China of around JPY 5.3 billion. Excluding it, royalty revenues grew approximately 43%.6 The two figures tell different stories depending on the baseline, and both come from the same source.
Pipelines: stated timelines, not results
Several smaller companies gave schedules. Ernexa says it remains on track to file its IND application for ERNA-101 (the request to begin human testing) in Q3 2026, with a first-in-human Phase 1 trial expected in Q4 2026.7 The source is a promotional-style newswire roundup, and only 35% of 3,660 claims checked against that source held up.7 Prelude Therapeutics said it expected to file an IND for PRT13722 by mid-2026 and start a Phase 1 study in ER-positive breast cancer in the second half of 2026.8 We found no confirmation in the dossier that the filing happened. Akari Therapeutics plans Phase 1 development of AKTX-101 in mid-2027 and describes patients whose cancers no longer respond to antibody-drug conjugates as a growing unmet need.9 These are company plans, not outcomes.
Hiring is also visible. Idorsia appointed Begoña Carreño-Gómez as Chief Business Development Officer, effective 1 November 2026.10 A business development chief is the executive who negotiates partnerships, so the appointment suggests deal-making is an expected activity. It does not show that any deal is close.
AI meets biology: early, and weakly sourced
Radical Numerics says AI-designed viruses have treated its first patient, with an experimental treatment aimed at drug-resistant E. coli.11 The only source is a technology newsletter. Via News has measured that publication's record at 6% of 16 checked claims holding up, a small sample but a poor result.11 The topic brief also mentions an AI agent that carried out a brain injection. Nothing in our verified record supports that, so we do not report it as fact.
The same caution applies to Generation Lab, which says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."12 That is the company's marketing language, and the claim has not been tested in what we hold. Elsewhere, OPKO Biologics reported that in vitro, which means in laboratory dishes rather than patients, its candidate OPK8801001 "showed ~20-fold greater growth hormone receptor antagonism than established Pegvisomant therapy."13 The finding is early, and results in cells often fail to carry over to people.
One further signal: UroGen's Chief Medical Officer, Mark Schoenberg, sold 10,000 shares worth $400,000 on 9 July 2026, after a 191% run in the stock.14 He said the sale ran under a Rule 10b5-1 plan adopted on 15 August 2025 that provides for automated execution. He described it as the concluding transaction of that plan's schedule.14 Pre-scheduled sales like this are generally less informative about an executive's view than discretionary ones.
The funding question
The wider backdrop weakened. Besides the selloff, OpenAI cut its funding target by $10 billion on 31 October.15 That is roughly three times Incyte's entire Q3 2026 cash balance.3,15 On 1 November, Binance users withdrew $3.6 billion when the exchange reopened on Sunday after a hack.16
Via News's analysis frames this period as a divergence: steady clinical and corporate progress in biotech alongside stress in AI-linked finance. That is our reading, not a verified finding. The dossier shows both halves but contains no data linking them, such as funding rounds that were cancelled or investor flows out of biotech. It is therefore too early to say that AI-bio capital will dry up. The companies with the clearest funding position, such as Incyte with $3.28 billion in cash, are not dependent on AI-market sentiment on the evidence we hold.3 The earliest-stage AI-bio claims, by contrast, rest on weak sources.
What to watch
- Whether Vor's two-year data is independently published or reviewed, and how regulators respond.
- Whether Ernexa files its IND in Q3 and Prelude confirms its filing, given that both timelines have now arrived or passed.7,8
- Incyte's next reported cash and cost-of-revenue figures, and whether the identical capital-spending entries are corrected or confirmed.3,5
- Any independent evidence for the Radical Numerics patient treatment.11
- Whether the equity and funding weakness in AI spreads to biotech financing rounds. That would be the first hard evidence for the worry in the topic brief.
